Drug intelligence / Profile preview

WX-mPD-L1

Development stage: Preclinical
Lead developer: WuXi AppTec
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

WX-mPD-L1 is an anti-mouse programmed death-ligand 1 (PD-L1) monoclonal antibody developed by WuXi AppTec and WuXi Biologics. It is designed as a surrogate research tool for use in syngeneic mouse xenograft models to evaluate the efficacy and mechanism of action of immune checkpoint inhibitors in preclinical settings. The antibody blocks the interaction between PD-L1 and its receptor PD-1, thereby enhancing T-cell mediated anti-tumor immune responses. It has been utilized in studies involving melanoma cell lines like CloudmanS91 and B16-F10 to profile neo-antigens and TCR repertoires.

Other names: anti-mouse PD-L1 antibodyWuXi anti-mouse PD-L1

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on WX-mPD-L1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WX-mPD-L1.

Explore the full profile